How did the last year play out for your coverage, and what do you see going forward? Are you optimistic? Dr. Nierengarten: Yes, I am optimistic. The reasons are based on what we saw happening last ...

So it’s been a few years since we last spoke. Let’s start with a brief overview and history of the company. Mr. Itescu: Sure. So Mesoblast has been publicly listed both on Nasdaq and the Australian ...

To start things off, I understand Vaxart is researching oral vaccines for COVID-19, norovirus, and influenza. Could you give us an overview of each program and where they are in the development ...

Recently you wrote a wonderful article that was published in Forbes magazine. In the context of an introduction to your coverage, what inspired you to write that piece, and what are some of the main ...

We’ve spoken several times before, but can you just give our readers a brief refresher on the company and how it has evolved over the years? Mr. Do: BioVie is a biotech company that started developing ...

Let’s start with a brief overview of the company — how it started and some milestones. Mr. Fried: The company was started back in the Bronze Age, 25 years ago. It was started by its current founder ...

Interview with Ryan Zimmerman, Managing Director and Medical Technology Analyst, BTIG and former Director of Surgery at ...

Complete Access to New Interviews, the Archive, and all Special Reports.